FDA scientists voted against new peptide rules

Consumers of injectable wellness compounds will soon have more legal avenues to purchase specific peptides in the United States. The Department of Health and Human Services posted a new policy document on Wednesday that instructs the Food and Drug Administration to refrain from acting against specialty pharmacies that sell six specific substances. These include BPC-157, TB-500, and KPV, which are marketed for muscle building and injury healing. Under current agency rules, these chemicals are considered illegal drugs because they have not passed the standard review process for safety and effectiveness.

The shift marks a change in how the government handles these compounds. For years, the FDA has maintained primary authority over compounding decisions. That authority was reinforced after a 2012 fungal meningitis outbreak traced to a Massachusetts pharmacy. Compounding has since grown into a multibillion dollar industry serving hospitals and clinics. Former FDA officials noted that it is rare for HHS to lead policy drafting in this area, though federal law grants HHS overarching authority that it typically delegates to the FDA.

Health Secretary Robert F Kennedy Jr has championed the move. He has described himself as a big fan of peptides and stated he used BPC-157 to treat a muscle injury. Kennedy argued that domestic compounding pharmacies must be permitted to sell these products to prevent Americans from buying gray market imports from China. Many current users order vials online from Chinese manufacturers who label items for research use only to avoid US regulations. The FDA warned in 2023 that adding such peptides to a do not compound list was necessary due to risks of allergic reactions, kidney damage, and tumor growth.

The policy development process revealed internal disagreement within the government. Six people familiar with the deliberations told the Associated Press that most scientific staff at the FDA opposed the plan. These staff members had limited input during the drafting phase. The current document represents a compromise from HHS initial intentions. Officials originally sought a formal regulation adding the peptides to a list of safe substances for compounding pharmacies. FDA scientists cited major safety concerns and refused to back that approach. HHS then pivoted to an enforcement directive that tells the agency not to police the sales.

Technical safeguards were added to the final document with help from FDA staff. The policy requires pharmacies to source peptide ingredients from FDA-registered factories. Compounders must also verify the chemical identity of the peptides and collect data on side effects for safety analysis. This structure avoids a direct conflict with agency scientists by limiting the scope to enforcement actions rather than safety declarations. Agency staff reiterated at a July meeting that more than a dozen peptides up for reconsideration remained unproven for safety and effectiveness.

The HHS office dedicated to protecting consumers from unsafe compounded drugs did not immediately respond to a request for comment regarding the new guidelines. The policy covers a handful of injectable peptides promoted in the wellness industry. The department aims to provide a regulated alternative to the online market where many buyers currently shop without medical oversight.